The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
Rattachement africain : de, jp, at, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Purpose Clinically accurate detection of prostate cancer (PCa) metastases is crucial for management of high-risk PCa patients scheduled for radical prostatectomy. We determine the safety and diagnostic accuracy of pre-operative 68 Ga-PSMA-11 PET/CT imaging in newly diagnosed high-risk PCa and assess its impact on patient management. Methods Investigator-initiated prospective multi-center multinational single-arm open-label phase 1/2 imaging trial (EuRadCT 2016–001815-19). Patients with high-risk PCa scheduled for prostatectomy were enrolled at 9 institutions in Germany, Austria, and Switzerland to undergo 68 Ga-PSMA-11 PET/CT for primary staging. The primary objectives were the evaluation of 68 Ga-PSMA-11 PET/CT imaging to detect the primary tumor and lymph node disease and safety assessment. Secondary objectives included detection of distant metastases, correlation of 68 Ga-PSMA-11 uptake with Gleason Score, and determining the impact on clinical management. Impact of pre-operative 68 Ga-PSMA-11 PET/CT imaging on target volume definition for radiation therapy was assessed. Results 173 patients underwent 68 Ga-PSMA-11 PET/CT for primary staging. Histopathologic correlation was available in 139 patients (imaging dataset), with lymph node metastases in 55 patients (39.6%). 20 treatment-emergent AEs unrelated to the test item were reported in 14 of 173 (8.1%) patients and no SAE occurred. On a per-patient basis, sensitivity of 68 Ga-PSMA-11 PET for local disease was 0.971 (95% CI, 0.928–0.992). Sensitivity, specificity, PPV, NPV and accuracy to detect local lymph node disease on a per-patient basis were 0.400 (95% CI 0.271–0.529), 0.988 (95%CI 0.965–1.000), 0.957 (95% CI 0.873–1.000), 0.716 (95% CI 0.633–0.798) and 0.755 (95% CI 0.684–0.827), respectively. Considering the intrinsic PET resolution of 3–5 mm, the exclusion of lesions smaller than 3 or 5 mm on histopathology from the analysis led to increased sensitivity of 56.4% and 69.0%, respectively. Median SUVpeak of local disease was 6.4 (range 1.7–13.6), 8.4 (range 2.3–39.4), 10.7 (range 5.6–23.0), and 13.4 (range 3.8–56.9) for Gleason Score 7a, 7b, 8 and 9, respectively. Based on the results of 68 Ga-PSMA-11 PET/CT, surgical intervention was canceled in 23 patients (13.2%). 68 Ga-PSMA-11 PET/CT resulted in a change of target volume delineation for radiation therapy planning in 29 patients (20.9%). Conclusion In high-risk primary PCa, 68 Ga-PSMA-11 is safe and effective in local staging, resulting in changes in both surgical and radiation management. Moreover, 68 Ga-PSMA-11 uptake is positively correlated with tumor grade and its efficacy is dependent on the size of nodal lesions. 68 Ga-PSMA-11 PET/CT will be highly impactful in the management of newly diagnosed high risk prostate cancer patients. Funding The study was funded by the German Cancer Consortium (DKTK).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
- Date Crossref
- 15/11/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Heidelberg University Department of Nuclear Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Heidelberg pays non établi dans la noticeÉtablissement de santé
-
Düsseldorf University Hospital pays non établi dans la noticeÉtablissement de santé
-
Heinrich Heine University Düsseldorf pays non établi dans la noticeUniversité ou école supérieure
-
The University of Osaka pays non établi dans la noticeUniversité ou école supérieure
-
Krankenhaus Barmherzige Brüder pays non établi dans la noticeÉtablissement de santé
-
Essen University Hospital pays non établi dans la noticeOrganisme public
-
University of Freiburg Institute for Surgical Pathology pays non établi dans la noticeUniversité ou école supérieure
-
University of Rostock pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Münster pays non établi dans la noticeÉtablissement de santé
-
Medizinische Hochschule Hannover pays non établi dans la noticeUniversité ou école supérieure
-
Technical University of Munich pays non établi dans la noticeUniversité ou école supérieure
Department of Nuclear Medicine — Heidelberg University, University Hospital Heidelberg et Düsseldorf University Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.